Prevention of drug-related complications in cystic fibrosis

Renske van der Meer*, Daan J Touw, Harry G M Heijerman

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

PURPOSE OF REVIEW: Due to continuous development of new drugs and better treatment strategies, survival of patients with cystic fibrosis has changed dramatically. Recently, targeted therapy of cystic fibrosis transmembrane conductance regulator (CFTR) modulators have become available. Despite these promising developments, treatment of this complex multiorgan disease constitutes a high and variable amount of other drugs. Complications of pharmacotherapeutic treatment are, therefore, expected to become more prevalent. This gives cause to review drug-related side effects in this new era in cystic fibrosis treatment.

RECENT FINDINGS: We will discuss cystic fibrosis-related pharmacotherapies with a focus on indication of treatment, side effects and their complications, drug--drug interactions, and options to monitor and prevent drug-induced toxicity. Many recent publications about pharmacotherapy in cystic fibrosis, focus on antifungal therapy and CFTR modulators. We will give an overview of the most important studies.

SUMMARY: With increased life expectancy which is, in part, because of better treatment options, the burden of pharmacotherapy in cystic fibrosis patients will increase. This has a high impact on quality of life as pharmacotherapy is time consuming and may cause side effects. Therefore, it is very important to be aware of possible pharmacotherapy-related side effects and their complications, drug--drug interactions, and options to monitor and prevent drug-induced toxicity.

Original languageEnglish
Pages (from-to)666-673
Number of pages8
JournalCurrent Opinion in Pulmonary Medicine
Volume25
Issue number6
Early online date9-Sep-2019
DOIs
Publication statusPublished - Nov-2019

Cite this